当前位置:
首页
网刊
血小板生成素受体激动剂治疗免疫性血小板减少症的新药研发进展
血小板生成素受体激动剂治疗免疫性血小板减少症的新药研发进展
张 珂1,2,雷 慧1,2,陈 曦1,2,赵 欣1,2,孙 懿1,2,蒲小平1,2

1 北京大学天然药物及仿生药物国家重点实验室,北京 100191; 2 北京大学药学院分子与细胞药理学系,北京 100191
Progress in new drug research and development of thrombopoietin  receptor agonists against immune thrombocytopenia
(1 State Key Laboratory of Beijing University of Natural and Biomimetic Drugs, Beijing 100191,China; 2 Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Science,  Peking University, Beijing 100191,China)

摘要参考文献相关文章

起始页:2380

摘要:[摘要] 免疫性血小板减少症(immune thrombocytopenia,ITP)是一种免疫介导的血小板过度破坏或生成不足导致的常见出血性疾病,以血小板减少和出血为主要症状。临床上包括以糖皮质激素、免疫抑制剂的药物治疗及脾脏切除术的外科手术治疗,从而减少血小板的破坏。随着对疾病机制的深入了解,针对巨核细胞增殖分化以增加血小板生成的一类药物血小板生成素受体激动剂(thrombopoietin receptor agonists,TPO-RAs,TRAs)成为ITP治疗的新途径。本文对TRAs类药物治疗ITP的新药研发现状进行综述。

关键词:[关键词] 免疫性血小板减少症;血小板生成素;血小板生成素受体激动剂

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] Immune thrombocytopenia (ITP) is an acquired common hemorrhagic condition characterized by a low platelet count and hemorrhage, which is caused by excessive platelet destruction and thrombopoiesis deficiency. Clinical therapy includes pharmacotherapy with corticosteroids and immunosuppressants and surgical treatment of splenectomy in order to reduce the destruction of platelets. With the deep understanding of the pathogenesis and etiology of ITP, thrombopoietin receptor agonists (TPO-RAs,TRAs) become a new way of ITP treatment, which increases platelet production by stimulating megakaryocytes. In this article, the status of research and development of TRAs for the treatment of ITP is reviewed.

Key words:[Key words] immune thrombocytopenia; thrombopoietin; thrombopoietin receptor agonists

    [1] NEUNERT C, NOROOZI N, NORMAN G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review[J]. JTH, 2015, 13(3): 457-464.
    [2] RODEGHIERO F, RUGGERI M. ITP and international guidelines: what do we know, what do we need?[J]. Presse Med, 2014, 43(4 Pt 2): e61-e67.
    [3] PROVAN D, NEWLAND AC. Current management of primary immune thrombocytopenia[J].Adv Ther, 2015, 32(10): 875-887.
    [4] NOMURA S. Advances in diagnosis and treatments for immune thrombocytopenia[J]. Clin Med Insights Blood Disord, 2016, 9: 15-22.
    [5] KASHIWAGI H, TOMIYAMA Y. Pathophysiology and management of primary immune thrombocytopenia[J]. Int J Hematol, 2013, 98(1): 24-33.
    [6] STASI R, BOSWORTH J, RHODES E,et al. Thrombopoietic agents[J]. Blood Rev, 2010, 24(4-5): 179-190.
    [7] LIU XG, LIU S, FENG Q,et al. Thrombopoietin receptor agonists shift the balance of Fcgamma receptors toward inhibitory receptor IIb on monocytes in ITP[J]. Blood, 2016, 128(6): 852-861.
    [8] 黄琼, 陈文生, 董进,等. 免疫球蛋白受体作为药物靶点的研究[J]. 中国药理学通报, 2016,32(2): 155-158.
    [9] YAZDANBAKHSH K. TPO-RAs multitask in ITP[J]. Blood, 2016, 128(6): 750-751.
    [10] ZHOU H, XU M, QIN P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP[J]. Blood, 2015, 125(10): 1541-1547.
    [11] 魏炜. 大剂量地塞米松联合rhTPO治疗初治重症原发免疫性血小板减少症疗效观察[J]. 中国继续医学教育, 2016, 8(33): 202-204.
    [12] NEWLAND A. What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists[J].Med Princ Pract, 2011, 20(4): 301-302.
    [13] WANG L, GAO Z, CHEN XP, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis[J].Sci Rep, 2016, 6: 39003.
    [14] NEWLAND A, GODEAU B, PRIEGO V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study[J].Br J Haematol, 2016, 172(2): 262-273.
    [15] STEURER M, QUITTET P, PAPADAKI HA,et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice[J].  Eur J Haematol, 2017, 98(2): 112-120.
    [16] MARSHALL AL, SCARPONE R, DE GREEF M, et al. Remissions after long-term use of romiplostim for immune thrombocytopenia[J]. Haematologica, 2016, 101(12): e476-e478.
    [17] CARPENEDO M, CANTONI S, COCCINI V, et al. Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice[J]. Hematol Rep, 2015, 7(1): 5673.
    [18] MAHEVAS M, FAIN O, EBBO M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study[J].Br J Haematol, 2014, 165(6): 865-869.
    [19] CHALMERS S, TARANTINO MD. Romiplostim as a treatment for immune thrombocytopenia: a review[J]. J Blood Med, 2015, 6: 37-44.
    [20] RIZVI H, BUTLER T, CALAMINICI M, et al. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings[J]. Br J Haematol, 2015, 169(4): 590-594.
    [21] CINES DB, GERNSHEIMER T, WASSER J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim[J]. Int J Hematol, 2015, 102(3): 259-270.
    [22] TARANTINO MD, BUSSEL JB, BLANCHETTE VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study[J]. Lancet, 2016, 388(10039): 45-54.
    [23] NEUNERT C, DESPOTOVIC J, HALEY K,et al. Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of North America ICON2 Study[J]. Pediatr Blood Cancer, 2016, 63(8): 1407-1413.
    [24] YANG R, LI J, JIN J,et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia[J]. Br J Haematol, 2017, 176(1): 101-110.
    [25] DEPRE F, ABOUD N, MAYER B, et al. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review[J]. Blood Transfus, 2017, 25: 1-6.
    [26] GRAINGER JD, LOCATELLI F, CHOTSAMPANCHAROEN T,et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial[J]. Lancet, 2015, 386(10004): 1649-1658.
    [27] BUSSEL JB, DE MIGUEL PG, DESPOTOVIC JM,et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study[J]. Lancet Haematol, 2015, 2(8): e315-e325.
    [28] NEUNERT CE, GRACE RF. Thrombopoietin-receptor agonists in children with immune thrombocytopenia[J]. Lancet, 2015, 386(10004): 1606-1609.
    [29] BUSSEL JB, KUTER DJ, ALEDORT LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia[J]. Blood, 2014, 123(25): 3887-3894.
    [30] ABE M, SUZUKI K, SAKATA C,et al. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist[J]. Eur J Pharmacol, 2011, 650(1): 58-63.
    [31] YAMANE A, NAKAMURA T, SUZUKI H,et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes[J]. Blood, 2008, 112(3): 542-550.
    [32] NAKAMURA T, MIYAKAWA Y, MIYAMURA A,et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis[J]. Blood, 2006, 107(11): 4300-4307.
    [33] NOGAMI W, YOSHIDA H, KOIZUMI K,et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis[J]. Haematologica, 2008, 93(10): 1495-1504.
    [34] KUTER DJ. New thrombopoietic growth factors[J]. Clin Lymphoma Myeloma, 2009, 9(Suppl 3): S347-S356.
    [35] NEUNERT CE, BUCHANAN GR, IMBACH P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura[J]. Blood, 2008, 112(10): 4003-4008.
    [36] 文瑞婷, 杨志刚, 龙杰, 等. 血小板生成素对血小板减少性疾病鉴别诊断及疗效判断的应用价值[J]. 中国实验诊断学, 2016, 20(6): 955-958.
    [37] FDA扩展了伊屈波帕治疗ITP的适应症

    [J].中国新药杂志,2015,24(17):1991.
    [38] 虞意华,严静. 重组人血小板生成素在脓毒性血小板减少症中的应用

    [J]. 中国现代应用药学,2015,32(8): 1028-1032.
    [39] 代燕平, 高小平, 吴建明, 等. 地榆总皂苷对巨核祖细胞增殖分化及相关受体表达的影响[J]. 中国中药杂志, 2014, 39(9): 1685-1689.
    [40] 田胜利, 许峰, 龚熠,等. 温肾清卫颗粒调控ITP患者TPO、PAIgG及c-MPL mRNA的临床研究[J]. 上海中医药杂志, 2010, 44(1): 53-55.
    [41] 王辰, 张珂, 李婉, 等. 淫羊藿苷元微乳制剂对小鼠免疫性血小板减少性紫癜模型的治疗作用[J]. 中国新药杂志, 2017, 26(5): 555-561.